Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Name: Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
License: Public Domain

M.D. Anderson Cancer Center

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

platinum

platinum-resistant fallopian tube carcinoma, platinum-resistant ovarian carcinoma, platinum-resistant primary peritoneal carcinoma, recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 261525
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.